News
The ENDEAVOUR lung cancer program, a three-year initiative designed to advance lung cancer research and care by connecting early-career oncologists in Europe with internationally renowned experts in ...
Stockhead on MSN16h
Scott Power: ASX health stocks up with capital raisings in full swingMorgans senior analyst Scott Power notes there's been a wave of capital raisings in the ASX healthcare sector as firms ...
Guide leverages Stream Hatchet’s influencer analytic and management capabilities to help creators understand campaigns and tactics to reach live streaming audiences The report highlights opportunities ...
Clinical Trials Arena on MSN7h
ASCO25: Volastra announces first-in-human data for KIF18A inhibitorVolastra Therapeutics has announced the preliminary data of its oral kinesin family member 18A (KIF18A) inhibitor, VLS-1488, ...
Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, today announced financial results for the first quarter ended March 31, 2025. Financial Results for the First Quarter ...
Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, today announced financial results for the first quarter ended March ...
Bruce Leuchter, CEO, Neurvati, discusses the indispensable role of patient advocates—particularly in rare and serious disease drug development—in shaping trial design, site selection, and regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback